Arthritis and Rheumatology Immunology

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Luna Sun, Yurong Chen, Ketan Marulkar, Natalia Bello, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie
Wiley · 2026-11-11 · DOI 10.1002/art.70375
⬢ Cited by: 0 Crossref

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →